As far as radiolabeled peptides are concerned, it is important to emphasize the increasing use of somatostatin (SST) analogues targeting somatostatin receptors (SSTR) in inflammatory diseases, particularly in rheumatoid arthritis (RA), Sjögren syndrome (SS), and autoimmune thyroid diseases. This evidence concerns the gene SST and synovial sarcoma.